Xu et al., 2022 - Google Patents
IFIT3 is increased in serum from patients with chronic hepatitis B virus (HBV) infection and promotes the anti-HBV effect of interferon alpha via JAK-STAT2 in vitroXu et al., 2022
View PDF- Document ID
- 2329623551996314251
- Author
- Xu S
- Huang J
- Xun Z
- Li S
- Fu Y
- Lin N
- Wu W
- Chen T
- Liu C
- Ou Q
- Publication year
- Publication venue
- Microbiology spectrum
External Links
Snippet
Increasing evidence indicates that interferon alpha (IFN-α) therapy is an effective treatment option for a subgroup of patients with chronic hepatitis B virus (HBV) infection. It has been confirmed that interferon-induced protein with tetratricopeptide repeats 3 (IFIT3), a member …
- 102100010000 IFIT3 0 title abstract description 166
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse Transcribing DNA Viruses
- C12N2730/00011—Reverse Transcribing DNA Viruses
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriphage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ye et al. | Interferon and hepatitis B: current and future perspectives | |
| Lahlali et al. | Novel potent capsid assembly modulators regulate multiple steps of the hepatitis B virus life cycle | |
| Tan et al. | When hepatitis B virus meets interferons | |
| Guo et al. | Activation of stimulator of interferon genes in hepatocytes suppresses the replication of hepatitis B virus | |
| Berke et al. | Capsid assembly modulators have a dual mechanism of action in primary human hepatocytes infected with hepatitis B virus | |
| Mao et al. | Indoleamine 2, 3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells | |
| Christen et al. | Inhibition of alpha interferon signaling by hepatitis B virus | |
| Campagna et al. | Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids | |
| Akhtar et al. | Viral exploitation of host SOCS protein functions | |
| Kanazawa et al. | Regulation of hepatitis C virus replication by interferon regulatory factor 1 | |
| Li et al. | Unusual features of sodium taurocholate cotransporting polypeptide as a hepatitis B virus receptor | |
| Li et al. | Interferon and interferon-stimulated genes in HBV treatment | |
| Xu et al. | IFN regulatory factor 1 restricts hepatitis E virus replication by activating STAT1 to induce antiviral IFN‐stimulated genes | |
| Tian et al. | Effects of interferon-α/β on HBV replication determined by viral load | |
| Schultz et al. | Elimination of duck hepatitis B virus RNA-containing capsids in duck interferon-alpha-treated hepatocytes | |
| Xu et al. | IFIT3 is increased in serum from patients with chronic hepatitis B virus (HBV) infection and promotes the anti-HBV effect of interferon alpha via JAK-STAT2 in vitro | |
| Winer et al. | Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection | |
| Leong et al. | Interferon-stimulated gene of 20 kDa protein (ISG20) degrades RNA of hepatitis B virus to impede the replication of HBV in vitro and in vivo | |
| Hao et al. | Inhibition of hepatitis B virus gene expression and replication by hepatocyte nuclear factor 6 | |
| Tsunematsu et al. | Hepatitis B virus X protein impairs α‐interferon signaling via up‐regulation of suppressor of cytokine signaling 3 and protein phosphatase 2A | |
| Jost et al. | Induction of antiviral cytidine deaminases does not explain the inhibition of hepatitis B virus replication by interferons | |
| Tsuge et al. | Development of a novel site-specific pegylated interferon beta for antiviral therapy of chronic hepatitis B virus | |
| Ma et al. | Glucose-regulated protein 78 is an intracellular antiviral factor against hepatitis B virus | |
| Park et al. | Antiviral activity of interferon‐stimulated gene 20, as a putative repressor binding to hepatitis B virus enhancer II and core promoter | |
| Uchida et al. | Persistent loss of hepatitis B virus markers in serum without cellular immunity by combination of peginterferon and entecavir therapy in humanized mice |